Biotech Startups

Z Biotic develops genetically engineered probiotics designed to improve daily health and wellbeing. The company uses biotechnology to create targeted probiotic products for consumers.

14 investors

Antiva Biosciences develops a topical therapeutic for women with high-risk HPV infection and pre-cancerous cervical lesions, utilizing antiviral prodrug chemistry. The company targets an unmet clinical need where no approved therapeutic options currently exist.

13 investors

Curebase provides a software platform for clinical trial management, serving contract research coordinators and trial sites. The platform emphasizes modern technology, data integrity, and compliance for advancing medical research.

13 investors

Gilead discovers, develops, and delivers innovative therapeutics for people with life-threatening diseases, focusing on virology, oncology, and inflammation across more than 35 countries. The company combines scientific rigor with global partnerships and licensing programs to expand access to medicines worldwide.

13 investors

Evidation collects and analyzes real-world health data from millions of community members to enable clinical research and health programs across various medical conditions. The platform partners with healthcare organizations, biomedical firms, government agencies, and nonprofits to drive discoveries and inform healthcare decision-making using everyday health data.

13 investors

Genome Medical provides telehealth-enabled genetic services, including genetic counseling, genetic testing, and clinical trial matching, with a focus on individuals with rare conditions. It partners with hospitals and health systems, life sciences organizations, and genetic testing labs to expand patient access and improve care.

13 investors

Genomelink develops a platform that provides individuals with access to and management of their genomic data, leveraging advances in DNA sequencing technology. The company serves consumers seeking personal genetic information and operates in the genomics and digital health sector.

13 investors

InnerPlant develops living sensor technology that enables farmers to detect plant stress in real-time, allowing targeted application of treatments to reduce chemical use and increase crop yields. The company serves agricultural producers seeking data-driven solutions for sustainable crop management.

13 investors

LabGenius develops EVA, an automated discovery engine for identifying and co-optimizing complex therapeutic antibodies such as multispecifics across multiple properties. Its internal pipeline focuses on selectivity-enhanced antibodies for treating solid tumours.

13 investors

LILA Sciences builds AI systems for autonomous scientific research and discovery across medicine, materials, energy, and defense sectors. The company develops a general-purpose platform designed to accelerate the scientific method by enabling systems to learn independently rather than relying on hard-coded expert knowledge.

13 investors

Ochre Bio develops RNA therapeutics and drug discovery platforms targeting liver disease, combining proprietary human liver datasets with AI-driven causal prediction and human tissue validation models. The company aims to address the global shortage of liver transplants by developing new treatment options for liver fibrosis and cirrhosis.

13 investors

Helicons develops a peptide-based therapeutic platform designed to target intracellular proteins previously considered undruggable by combining the specificity of antibodies with the cell-penetrating properties of small molecules. The platform uses AI and simulation to engineer helical peptides with non-canonical amino acids for precision binding across a range of therapeutic applications.

13 investors

Plantible Foods redesigns the food supply chain to advance health for people and the planet. The company operates in the foodtech and agtech sectors.

13 investors

Proscia provides a digital pathology software platform that converts glass microscope slides into high-resolution digital images for viewing, management, and analysis by pathologists and research teams. The platform enables clinical laboratories and life sciences organizations to improve workflow efficiency, support remote collaboration, and integrate artificial intelligence tools for quantitative tissue analysis and biomarker detection.

13 investors

Resilience is a contract development and manufacturing organization (CDMO) that manufactures complex pharmaceutical products and active pharmaceutical ingredients to broaden access to medicines and protect biopharmaceutical supply chains against disruption.

13 investors

Senti Bio develops cell and gene therapies for cancer and difficult-to-treat diseases using synthetic biology and engineered Gene Circuits to enhance precision, control, and selectivity in targeting tumor cells. The company is a clinical-stage biotech firm leveraging proprietary platform technology across multiple cell types and modalities.

13 investors

SelfWrap develops bioabsorbable wrap materials for vascular grafts that conform to individual patient anatomy and are designed to be absorbed by the body, unlike alloy-based alternatives. The company is developing the product for coronary and peripheral bypass grafting applications.

13 investors

Cytovale develops microfluidic deformability cytometry technology for immune response diagnostics, with a focus on early detection and diagnosis in hospital settings. The company serves healthcare systems and clinicians with diagnostic instruments and solutions.

12 investors

Alga Biosciences develops feed additives that reduce methane emissions from cattle — cutting cow burps to combat climate change.

12 investors

Big Hat Bio develops therapeutics under development across multiple programs. The company is a STEM-focused team working on therapeutic discovery and development.

12 investors

BioOrbit produces pharmaceutical-grade crystals in microgravity environments via space-based facilities, enabling development of biologic drugs and treatments for patients. The company bridges orbital research with terrestrial medicine to make advanced pharmaceutical manufacturing accessible beyond hospital settings.

12 investors

BIOAGE develops therapies targeting the molecular pathways that drive aging to increase healthspan and address age-related chronic diseases. The company uses data-driven approaches and bioinformatics to identify and develop its pipeline of aging-focused therapeutics.

12 investors

C16 Biosciences produces high-value lipid ingredients using fermentation of naturally occurring microorganisms for manufacturers of beauty, personal care, home care, and food products. The company's biomanufacturing platform enables sustainable production with 250x greater land efficiency than traditional ingredient sources.

12 investors

DELFI Diagnostics develops FirstLook Lung, a blood-based laboratory test for lung cancer screening that identifies genome-wide alterations in individuals eligible for screening. The test offers an alternative to low-dose CT imaging for patients meeting USPSTF criteria and is made available to health systems, primary care providers, and lung screening programs.

12 investors